Detecting retinal vigabatrin toxicity in patients with partial symptomatic or cryptogenic epilepsy

European Journal of Ophthalmology

Volumn 20, Issue 4, 2010, Pages 763-769

  Akçakaya, Aylin Ardagil ^a   Gökçeer, Sevda ^a   Erbil, Hasan H ^a   Işik, Nihal ^a   Özdöker, Levent ^a   Salar, Senem ^a   Aykan, Fatma ^a   Aydin, Tuǧrul ^a   Yaylali, Sevil Ari ^a   Kesim, Özlem ^a  

^a GOZTEPE TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Cryptogenic epilepsy; Partial symptomatic epilepsy; Vigabatrin toxicity

Indexed keywords

CARBAMAZEPINE; VALPROIC ACID; VIGABATRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COLOR DISCRIMINATION; COLOR VISION; CONTRAST SENSITIVITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC VALUE; FEMALE; FOCAL EPILEPSY; HUMAN; MALE; OBSERVATIONAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; PERIMETRY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA INJURY; RETINA NERVE CELL; SYMPTOMATIC EPILEPSY;

EID: 77955809785     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067211002000419     Document Type: Article

References (22)

1. Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD. Vigabatrin: 2008 update. Epilepsia 2009; 50: 163-73.
2. Wheless JW, Ramsey RE, Collins SD. Vigabatrin. Neurotherapeutics 2007; 4: 163-72.
3. Kälviäinen R, Aikiä M, Saukkonene AM, Mervaala E, Riekkinen PJ Sr. Vigabatrin versus carbarnazepine monotherapy in newly diagnosed patients with epilepsy. Arch Neurol 1995; 52: 989-96.
4. Mackay MT, Weiss SK, Adams-Weber T, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology: Child Neurology Society. Neurology 2004; 62: 1668-81.
5. Nousiainen I, Kalviainen R, Mantyjarvi M. Contrast and glare sensitivity in epilepsy patients treated with vigabatrin or carbamazepine monotherapy compared with healthy volunteers. Br J Ophthalmol 2000; 84: 622-5. (Pubitemid 30339315)
6. Kinirons P, Cavalleri GL, OíRourke D, Doherty CP, Reid I, Logan P. Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose. Epilepsia 2006; 47: 311-7.
7. Buncic JR, Westall CA, Panton CM, Munn JR, MacKeen LD, Logan WJ. Characteristic retinal atrophy with secondary ëInverseí optic atrophy identifies vigabatrin toxicity in children. Ophthalmology 2004; 111: 1935-42.
8. Engel J. Classifications of the International League Against Epilepsy: time for reappraisal. Epilepsia 1998; 39: 1014-7. (Pubitemid 28413423)
9. Pittau F, Bisulli F, Mai R, et al. Prognostic factors in patients with mesial temporal lobe epilepsy. Epilepsia 2009; 50 (Suppl 1): S41-4.
10. Nagata S, Morioka T, Matsukado K, Natori X Sasaki T. Retrospective analysis of the surgically treated temporal lobe arteriovenous malformations with focus on the visual field defects and epilepsy. Surg Neurol 2006; 66: 50-5; discussion 55.
11. Engel JR, Pedley TA. West syndrome. In: Epilepsy: A Comprehensive Textbook, 2nd edition. Baltimore: Lippincott Williams & Wilkins; 2008: 2332-3.
12. Trojan H. Visual field findings in symptomatic epilepsy. Klin Monatsbl Augenheilkd 1967; 150: 718-21.
13. Van Mil SG, Reijs RP, va Hall MH, Snoeijen SM, Aldenkamp AP Behavioral status of children with cryptogenic localization- related epilepsy. J Child Neurol 2009; 24: 449-53.
14. Wild JM, Robson CR, Jones AL, Cunliffe IA, Smith PEM. Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. Invest Ophthalmol Vis Sci 2006; 47: 917-24.
15. Pow DV, Baldrige W, Crook DK. Activity-de pendent transport of GABA analogues into specific cell types demonstrated at high resolution using a novel immunocytochemical strategy. Neuroscience 1996; 73: 1129-43.
16. Ravindran J, Blumbergs P, Crompton J, Pietris G, Waddy H. Visual field loss associated with vigabatrin: pathological correlations. J Neurol Neurosurg Psychiatry 2001; 70: 787-9. (Pubitemid 32554211)
17. Schuman JS, Pedut-Kloizman T, Hertzmark E, Hee MR, Wilkins JR, Coker JG. Reproducibility of nerve fiber layer thickness measurements using optical coherence tomography. Ophthalmology 2003; 110: 190-5.
18. Arndt CF, Salle M, Derambure PH, Defoort-Dhellemmes S, Hache JC. The effect on vision of associated treatments in patients taking vigabatrin: carbarn azepine versus valproate. Epilepsia 2002; 43: 812-7. (Pubitemid 34857855)
19. Nousiainen I, Kalviainen R, Mantyjarvi M. Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy. Ophthalmology 2000; 107: 884-8.
20. McDonagh J, Stephen LJ, Dolann FM, Parks S, Dutton GN, Kelly K. Peripheral retinal dysfunction in patients taking vigabatrin. Neurology 2003; 61: 1690-4. (Pubitemid 38020813)
21. Nousiainen I, Kalviainen R, Mantyjarvi M. Contrast and glare sensitivity in epilepsy patients treated with vigabatrin or carbarn azepine monotherapy compared with healthy volunteers. Br J Ophthalmol 2000; 84: 622-5. (Pubitemid 30339315)
22. Hawker MJ, Astbury NJ. The ocular side effects of vigabatrin (Sabril): information and guidance for screening. Eye 2008; 22: 1097-8.